UNSPSC 51172123: Dexsecoverine or dexsecoverine hydrochloride

This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formulas C22H35NO2 and C22H35NO2.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 3O6AUX3I0J and B8042DUA17. European Medicines Agency schedules Dexsecoverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07047MIG.

The term DEXSECOVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) DEXSECOVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dexsecoverine and its salts under HS 29225000 and SITC 51467. As of Q4 2014, DEXSECOVERINE remains the US FDA Preferred Term for this commodity. Dexsecoverine bears US NLM NCI C73161 and C97977.

UNSPSC 51172123 Dexsecoverine or dexsecoverine hydrochloride is a Commodity code with minimal recent state and local procurement activity directly aligned to this specific pharmaceutical substance. The three most recent opportunities tagged to this code span offender drug testing, a preliminary state-level information-gathering initiative on direct-to-manufacturer pharmacy programs, and a cooperative purchasing agreement for generic multi-source pharmaceuticals and OTC products. Only one of these—the Collin County offender testing RFP—involves specimen collection and screening services where confirmatory drug testing methodologies (including immunoassay and LC/MS/MS or GC/MS confirmation) may require reference standards or reagent components; the other two opportunities are exploratory or aggregate-level purchasing arrangements that do not indicate direct procurement of dexsecoverine or related testing compounds at the commodity level.

Issuing bodies represent a narrow mix: a single Texas county community supervision department, a state HHS commission conducting market research, and a multi-state cooperative purchasing alliance. The Collin County Community Supervision and Corrections Department RFP, due July 23, 2026, is the most concrete opportunity, seeking specimen collection and drug testing services for approximately 25,031 annual tests across five-panel and six-panel immunoassay screening with confirmatory testing, with an estimated contract value of $600,000 over two years plus optional renewals. Activity is concentrated in Texas, with Minnesota and Oregon represented only through the cooperative purchasing vehicle. The code shows little recent activity targeting dexsecoverine as a named commodity, and the tagged opportunities suggest either misclassification of the code or minimal state and local direct procurement of this specific pharmaceutical substance under current solicitation practices.